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Abstract: Background: Hepatic myofibroblasts (MFs) can originate from hepatic stellate cells, portal
fibroblasts, or bone marrow-derived mesenchymal stem cells and can migrate towards the site of injury
by aligning with nascent and established fibrotic septa in response to several mediators. Oncostatin M
(OSM) is known to orchestrate hypoxia-modulated hepatic processes involving the hypoxia-inducible
factor 1 (HIF-1). Methods. In vivo and in vitro experiments were performed to analyze the expression
of OSM and OSM-receptor (OSMR) in three murine models of non-alcoholic-fatty liver disease
(NAFLD) and -steatohepatitis (NASH) and in human NASH patients as well as the action of OSM on
phenotypic responses of human MFs. Results: Hepatic OSM and OSMR levels were overexpressed
in three murine NASH models and in NASH patients. OSM stimulates migration in human MFs
by involving early intracellular ROS generation and activation of Ras/Erk, JNK1/2, PI3K/Akt as well
as STAT1/STAT3 pathways and HIF-1α. OSM-dependent migration relies on a biphasic mechanism
requiring early intracellular generation of reactive oxygen species (ROS) and late HIF1-dependent
expression and release of VEGF. Conclusion: OSM is overexpressed in experimental and human
progressive NAFLD and can act as a profibrogenic factor by directly stimulating migration of
hepatic MFs.
Keywords: Oncostatin M; liver fibrosis; NAFLD/NASH; myofibroblasts; migration; reactive oxygen
species; VEGF-A
1. Introduction
During chronic liver diseases (CLDs), liver fibrogenesis is sustained by an heterogeneous
population of myofibroblast-like cells (MFs) that can originate mainly from hepatic stellate cells
(HSC/MFs) and portal (myo)fibroblasts or, to a less extent, circulating and bone marrow-derived
mesenchymal stem cell (MSCs) engrafting chronically injured liver [1–6]. At present, the involvement
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of epithelial to mesenchymal transition (EMT) as pro-fibrogenic mechanism leading to the origin of
MFs from hepatocytes and/or cholangiocytes in progressive CLD is likely to be of minor relevance,
as suggested by several elegant but mostly negative fate tracing studies [7–11]. In the scenario of
pro-fibrogenic phenotypic responses of hepatic MFs, their migration towards the site of injury and their
ability to align with nascent and established fibrotic septa in response to several stimuli (polypeptide
mediators, hypoxia, reactive oxygen species or ROS) is considered as a relevant issue [4,12,13].
During CLD many peptide mediators, including platelet-derived growth factor (PDGF), monocyte
chemoattractant protein-1 (MCP-1 or CCL2), angiotensin II (AT-II), vascular endothelial growth
factor-A (VEGF-A) as well as ROS and/or hypoxic conditions, have been reported to stimulate
HSC/MFs migration, then contributing to fibrosis progression [12–17]. Along these lines, OSM,
a pleiotropic cytokine structurally and functionally related to the interleukin-6 (IL-6) cytokine family,
has recently emerged as a mediator involved in CLDs progression [18–24]. OSM acts through the Janus
kinase/signal transducer and activator of transcription (JAK/STAT) pathway and mitogen-activated
protein kinases (MAPK) in order to critically regulate processes such as liver development and
regeneration, hematopoiesis, and angiogenesis [23]. Remarkably, these processes are also regulated
by hypoxia through the involvement of hypoxia-inducible factor 1 alpha (HIF1α). A previous study
by Vollmer and colleagues [19] showed that HIF1α levels increased significantly after treatment of
hepatocytes and hepatoma cells with OSM. These Authors also showed that HIF1α contributed to
OSM-downstream signaling events, suggesting the existence of a cross-talk between OSM and hypoxia
signaling in liver development and regeneration. Moreover, OSM is known to affect and regulate
inflammatory response in several diseases affecting different organs and tissues [20]. Concerning
the liver, in addition to the role in development and regeneration [23] as well as inflammatory
response [20] OSM has been suggested to be involved also in the pathogenesis of steatosis and hepatic
insulin resistance [21]. OSM is expressed in Kupffer cells even in normal liver but it is consistently
over-expressed in cirrhotic livers [18]. OSM can signal through 2 different heterodimeric receptors that
share gp130 (a common subunit receptor for ligands of IL-6 family) and involve either leukemia inhibitor
factor receptor β (LIFRβ) or OSM receptor β (OSMRβ). In particular, LIFRβ is weakly expressed
in normal livers, but more intensely in cirrhotic liver, in reactive ductules, bile ducts, colangiocytes,
and perisinusoidal areas; OSMRβ is expressed at low level in hepatocytes of normal livers, but is was
reported to be unchanged in cirrhotic samples. Moreover, in a study from the same research group [22]
it was reported that OSM was able to modulate response of HSC/MFs by increasing collagen I and
tissue inhibitor of metalloproteinase-1 (TIMP-1) secretion, suggesting a putative pro-fibrogenic role for
OSM in CLD. More recently, a mechanistic experimental study has confirmed the ability of OSM to
act as a pro-fibrogenic mediator by regulating both macrophage (resident and bone marrow-derived)
and, as a consequence, MFs activation during the course of thioacetamide (TAA)-induced model of
CLD [24]. These authors showed that OSM up-regulated the expression of pro-fibrogenic mediators
such as TGF-β and PDGF in macrophages, suggesting that OSM may be indirectly pro-fibrogenic by
up-regulating through TGF-β and PDGF, collagen and TIMP1 synthesis in HSC/MFs. In the mentioned
study, liver fibrosis was significantly prevented in OSM knockout mice submitted to the TAA protocol
vs related control littermates. Moreover, continuous expression of OSM in normal mouse liver, as forced
by means of hydrodynamic tail vein injection (HTVi), resulted in severe fibrosis [24]. In the present
study, we investigated the involvement of OSM in experimental and human NAFLD/NASH and we
performed experiments in order to elucidate whether this cytokine may act directly on LX2 cells and
primary culture of human HSC/MFs by regulating selected pro-fibrogenic phenotypic responses.
2. Materials and Methods
Materials: The methionine and choline-deficient (MCD) diet, the choline-deficient amino
acid-refined (CDAA) diet, the high fat–high fructose diet (HFHF) as well as the related control
diets, methionine choline supplemented (MCS) diet and choline-supplemented and amino acid-refined
(CSAA) diet and normal (not supplemented with fat) diet were provided by Laboratorio Dottori
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Piccioni srl (Gessate, Milano, Italy). The kit for RNA retro-trascription and for real time PCR were
purchased from Biorad (Berkely, CA, USA). Enhanced chemiluminescence (ECL) reagents, nitrocellulose
membranes (Hybond-C extra) were from Amersham Pharmacia Biotech Inc. (Piscataway, NJ, USA).
Human recombinant Oncostatin M (OSM) was from Petrotech (Rocky Hill, CT, USA). Monoclonal
antibody against p-ERK1/2 (sc-7383), polyclonal antibody for p-STAT1 (sc-8394), STAT1 (sc-346),
p-STAT3 (sc-8059), STAT3 (sc-7179), ERK1/2 (sc-292838), p-Akt1/2/3 (sc-7985-R), Akt1/2/3 (sc-8312),
VEGF (sc-152), and HIF-1α (sc-10790) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Polyclonal antibody for p-JNK and JNK1/2 were from Cell Signaling Technology (Danvers, MA, USA).
PD98059, SP600125, LY294002 and apocynin were from Calbiochem (La Jolla, CA, USA). Monoclonal
antibodies for β-actin, crystal violet, DCFH-DA and all other reagents of analytical grade as well
as primers for RT-PCR were from Sigma Chemical Co (Sigma Aldrich Spa, Milan, Italy), Boyden’s
chambers were from Neuro Probe, Inc. (Gaithersburg, MD, USA). The monoclonal neutralizing
antibody against Flk-1 was obtained from ImClone (New York, NY, USA).
Methods: Animal experimentation. In this study we used three different dietary protocols for
induction of progressive NAFLD that were carried out in 8 week old C57Bl/6 mice (Harlan Laboratories,
Indianapolis, IN, USA) (n = 8 for any experimental group). Mice were fed as previously described [25]
on the following dietary regimens: (i) Methionine and choline-deficient (MCD) diet or methionine
and choline sufficient (MCS) control diet, (ii) choline-devoided and L-amino acid-defined (CDAA)
diet or choline-sufficient L-amino acid-defined (CSSA), (iii) high fat–high fructose (HFHF) diet. Mice
were then sacrificed at different experimental time points (4 days, 2, 4, and 8 weeks for MCD or MCS
protocol, 12 and 24 weeks for CDAA or CSAA protocol, 24 weeks for HFHF and standard control
diet). Mice were kept under specific pathogen-free conditions and maintained with free access to pellet
food and water. Liver samples were obtained and immediately used/processed for morphological
or molecular biology analyses or frozen and thereafter maintained at −80 ◦C for further analysis.
The experiments complied with EU and national ethical guidelines for animal experimentation and
all experimental protocols were approved by the Animal Ethic Committee of University of Oriental
Piedmont, Novara, Italy and Italian Ministry of Health.
Human patients: The study on NASH patients was approved by the Ethics Committee of the
Azienda Ospedaliera Universitaria Città della Salute (Turin, Italy). For this study we analyzed liver
biopsies from NASH patients (n = 20) or from patients with simple steatosis (n = 10), referring to the
Division of Gastroenterology and Hepatology of the University of Turin. All samples were collected at
the time of first diagnosis; all subjects gave informed consent to the analysis, and the study protocol,
which conformed to the ethical guidelines of the 1975 Declaration of Helsinki, was planned according
to the guidelines of the local ethics committee.
Immunohistochemistry analysis: Liver sections from human patients with NASH or with simple
steatosis were employed. Immunostaining procedure was as previously described [25]. Briefly,
paraffin sections (2 µm thick), mounted on poli-l-lysine coated slides, were incubated with (i) the
monoclonal antibody against OSM (Santa Cruz Biotechnology, Dallas, TX, USA; dilution 1:200) or
(ii) the monoclonal antibody against human CD68 (Biorad, Hercules, CA, USA; dilution 1:80) or (iii) the
secondary monoclonal antibody alone, as negative control. After blocking endogenous peroxidase
activity with 3% hydrogen peroxide and performing microwave antigen retrieval in sodium citrate
buffer pH6, primary antibodies were labeled by using EnVision, HRP-labeled System (DAKO) and
visualized by 3′-diaminobenzidine substrate.
LX2 cells culture: Human LX2 cells, a model of immortalized and activated, MF-like, human HSC,
originally kindly provided by Prof. Scott L. Friedman (Icahn School of Medicine, MS, USA), were
cultured in Dulbecco’s modified Eagle’s medium (Sigma Aldrich Spa, Milan, Italy), supplemented with
10% fetal calf serum and 1% antibiotics. In most experiments we also used human HSCs (Clinisciences,
Nanterre, France), were used between passages 4 and 7 when showing a phenotype of fully activated,
MF-like HSCs (HSC/MFs), plated to obtain the desired sub-confluence level and then left for 24 h in
serum-free Iscove’s medium to have cells at the lowest level of spontaneous proliferation [13]. LX2
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cells or HSC/MFs were then exposed in culture conditions to human recombinant OSM 10 ng/mL for
different times.
Cell migration and Chemotaxis: Non-oriented migration (chemokinesis) and chemotaxis of
human LX2 (and HSC/MFs) were evaluated after exposure to PDGF-BB 10ng/mL, used as positive
control, or to OSM 10 ng/mL, by performing the wound healing assay (20 h of incubation) or the
modified Boyden’s chamber assay (6 h of incubation), as previously described [7,13]. For the wound
healing assay LX2 or HSC/MFs cells were plated on collagen coated 24 wells (Falcon, Corning, NY,
USA) and, were confluent, left for 24 h in their medium without serum to have cells at the lowest level
of spontaneous proliferation. Then, a scratch on the cell monolayer was performed and the cells were
exposed to medium with hrOSM (or where indicated with specific inhibitors) for 20 h, stained with
crystal violet and finally observed at contrast phase microscope.
For the Boyden’s chamber assay, filter of 8 µm (Whatman Nuclepore™ track-etched polycarbonate
membranes) were first coated with type I collagen (20 µg/mL) for 30 min at 37 ◦C.
2 × 104 cells were placed in the upper compartment and were allowed to migrate through the
pores of the filter into the lower compartment, in which chemotactic agents are present. At the end of
incubation time (6 h), filters were removed from the Boyden’s chamber and stained with crystal violet.
In some experiments, cells were pre-treated with specific inhibitors to check the relevance of specific
proteins in process described.
Proliferation: Proliferation of human LX2 cells (and HSC/MFs) was evaluated by crystal violet
proliferation assay by seeding cells in a 96-well plate at a density of 1.5 × 103 cells per well. The cells
were incubated in serum-free medium (SFM) for 24 h and then exposed to OSM 10 ng/mL. At the desired
time, the medium was removed, and the cells were washed twice with phosphate-buffered saline, fixed
with 11% glutaraldehyde; after fixation, cells were washed and then stained with 0.1% (w/v) crystal
violet solution for 10 min. After washing with water, the crystal violet was solubilized with 50 µL
of 10% acetic acid solution, and absorbance was measured at 595–650 nm using a microplate reader
(SpectraMAX M3; Molecular Devices, Sunnyvale, CA, USA). In some experiments, BrdU incorporation
assay was performed. LX2 cells or HSC/MFs were seeded in culture plates (1 × 104 cells per well,
96 multiwell), for 24 h up to 72 h. The cell proliferation rate was evaluated by means of a colorimetric
assay kit supplied by Roche Diagnostic (11647229001) according to manufacturer’s instructions.
Detection of intracellular generation of ROS. (A) DCFH-DA technique: Detection of ROS generation
in cultured cells was performed by using the semi-quantitative DCFH-DA technique as previously
described [7]. Cultured cells, seeded in 12-well culture plates (105 cells/well), were exposed to OSM
10 ng/mL for 15 min or pre-treated with apocynin for 1h and then exposed with OSM 10 ng/mL. ROS
generation was detected as the conversion of 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA,
1 µM) into the corresponding fluorescent derivative. Cells were observed and photographed under
a Leica fluorescence microscope (DMI 4000 B model). (B) combination of DCFH-DA technique and
flow cytometric analysis: cells were seeded in P35 dishes (5 × 105 cells/dish), cultured for 24 h and
exposed to OSM alone or OSM plus 250 nM apocynin for 1 h before addition of 5 µM DCFH-DA
(15 min of incubation in the dark). Cells were rapidly washed with PBS, collected by trypsinization,
briefly centrifuged (1600 rpm for 5 min) and re-suspended in PBS for analysis. Detection of DCF green
fluorescence (FL1) was performed on at least 5000 cells per sample with a FACScan equipped with a
488 nm argon laser using the CellQuest software (version 1.0.264.21, Becton-Dickinson, Milano, Italy).
The peak of FL1 intensity of DCFH-DA-stained control cells grown without OSM was set to channel
101 and retained for all measurements [24]. As a positive control, cells were treated with 100 µM H2O2
for 15 min, stained with DCFH-DA as above and assayed during the same analytical session.
Western blot analysis: Total cell lysates, obtained as described [7,11,24], were subjected to
sodium dodecyl sulfate-polyacrylamide gel-electrophoresis on 13.5%, 10%, or 7.5% acrylamide gels,
incubated with desired primary antibodies, then with peroxidase-conjugated anti-mouse or anti-rabbit
immunoglobulins in Tris-buffered saline-Tween containing 2% (w/v) non-fat dry milk and finally
developed with the ECL reagents according to manufacturer’s instructions. Sample loading was
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evaluated by reblotting the same membrane with the un-phosphorylated form of protein or with
β-actin antibody. In some experiments, protein levels in culture medium obtained from LX2 or
HSC/MFs exposed to OSM for the desired time were evaluated by an immunoprecipitation procedure,
as described previously [13].
Quantitative real-time PCR (Q-PCR): RNA extraction, complementary DNA synthesis, quantitative
real-time PCR (Q-PCR) reactions were performed as previously described [6,10]. mRNA levels were
measured by Q-PCR, using the SYBR® green method as described [25]. The amplification mix
was prepared using iTaq Universal Syber Green SuperMix (Biorad Laboratories, Berkeley, CA,
USA) following manufacturer’s instructions and realtime PCR was performed using Miniopticon
ThermoCycler Instrument (Biorad Laboratories, Berkeley, CA, USA). Oligonucleotide sequence of
primers used for RT-PCR were:
Primer Sense Reverse
murine OSM TTTCTCTGGGGATACCATCG GGAGACACGATGGGCTATGT
murine OSMβR GGAGACACGATGGGCTATGT CATCTGAGGTGATGGTGGTG
murine TBP CACATCACAGCTCCCCACCA AGCGGAGAAGATGCTGGAAAC
human OSM TACTGCTCACACAGAGGACGC CTATAGCCGCCATGCTCGC
human OSMR CGCGTCAGGTTTGCACTTA GTGTGTGGCACATTCCAAG
human LIFR GGCTCATCACCACCTTCCAA CCCCTTTCCCATCCCAACAA
human HIF1α CCACCTATGACCTGCTTGGT TATCCAGGCTGTGTCGACTG
human VEGF CCCACTGAGGAGTCCAACAT TTTCTTGCGCTTTCGTTTTT
human CCL2 CCCCAGTCACCTGCTGTTAT AGATCTCCTTGGCCACAATG
human IL6 AGGAGACTTGCCTGGTGAAA CAGGGGTGGTTATTGCATCT
human TNF-α AACCTCCTCTCTGCCATCAA GGAAGACCCCTCCCAGATAG
human GAPDH TGGTATCGTGGAGGACTCATGGAC ATGCCAGTGAGCTTCCCGTTCAGC
TATA binding protein (TBP) and Gliceraldehyde-3-phosphate dehydrogenase (GAPDH) were
used as internal reference for murine and human sample respectively, and co-amplified with target
samples using identical Q-PCR conditions. Samples were run in triplicate and mRNA expression was
generated for each sample. Specificity of the amplified PCR products was determined by melting
curve analysis and confirmed by agarose gel electrophoresis.
Statistical analysis: Data in bar graphs represent means ± SEM, and were obtained from
average data of at least three independent experiments. Luminograms and morphological images
are representative of at least three experiments with similar results. Statistical analysis for these
experiments was performed by Student’s t-test or ANOVA for analysis of variance when appropriate
(p < 0.05 was considered significant).
3. Results
3.1. OSM and OSMR Expression in Three Different Models of Experimental NASH and in Human
NASH Patients
In order to investigate the involvement of OSM and its receptor OSMβR in NAFLD/NASH
progression, mice were fed on MCD or CDAA or HFHF dietary protocols, all able to induce NAFLD
progressing to NASH and liver fibrosis [25]. The results obtained showed that hepatic transcript
levels for OSM and OSMβR significantly increased after 8 weeks of treatment in mice fed on the MCD
protocol (Figure 1A,B) as well as in mice fed for 12 and 24 weeks on the CDAA protocol (Figure 1C,D)
in parallel with increased collagen deposition and HSC/MF recruitment/activation, as previously
described [25]. OSM and OSMβR transcript levels also increased in liver samples from mice fed on
HFHF diet for 24 weeks (Figure 1E,F).
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Figure 1. (A,B) Increased gene expression of Oncostatin M (OSM) and OSM receptor β (OSMRβ) in 
methionine and choline-deficient (MCD) mice model. Quantitative real time PCR (q-PCR) analysis of 
OSM (A) and OSMβR (B) transcripts levels in control mice (MCS diet) and in mice fed with MCD diet 
for 4 days, 2, 4, and 8 weeks. Data are expressed as means ± SEM of three independent experiments 
(***p < 0.001, *p < 0.01 vs control mice.). (C,D) Increased gene expression of OSM and OSMβR in 
choline-deficient aminoacid-refined (CDAA) mice model. Quantitative real time PCR (q-PCR) 
analysis of OSM (C) and OSMβR (D) transcripts levels in control mice (CSAA diet) and in mice fed 
with CDAA diet for 12 and 24 weeks. Data are expressed as means ± SEM of three independent 
experiments (***p < 0.001, *p < 0.05 vs control mice). (E,F). Increased gene expression of OSM and 
OSMβR in high fat–high fructose diet (HFHF) mice model. Quantitative real time PCR (q-PCR) 
analysis of OSM (E) and OSMβR (F) transcript levels in control mice (standard diet) and in mice fed 
with HFHF diet for 24 weeks. Data are expressed as means ± SEM of three independent experiments 
(*p < 0.05 vs control mice). 
OSM transcript levels were significantly increased also in specimens obtained from NASH patients 
as compared to those obtained from patients showing simple steatosis (no NASH, Figure 2A); moreover, 
OSM immunostaining was also significantly increased in sections from liver biopsies from NASH patients 
and in cells characterized by macrophage-like morphology (i.e., CD68 positive) (Figure 2B). 
Figure 1. (A,B) Increased gene expression of Onc tatin M (OSM) and OSM receptor (OSMRβ) in
methionine and choline-deficient (MCD) mice model. Quantitative real time PCR (q-PCR) analysis of
OSM (A) and OSMβR (B) transcripts levels in control mice (MCS diet) and in mice fed with MCD diet
for 4 days, 2, 4, and 8 weeks. Data are expressed as means ± SEM of three independent experiments
(*** p < 0.001, * p < 0.01 vs c ntrol mice.). (C,D) Increas d gene expression of OSM and OSMβR in
choline-deficient aminoacid-refined (CDAA) mice model. Quantitative real time PCR (q-PCR) analysis
of OSM (C) and OSMβR (D) transcripts levels in control mice (CSAA diet) and in mice fed with CDAA
diet for 12 and 24 weeks. Data are expressed as means ± SEM of three independent experiments
(*** p < 0.001, * p < 0.05 vs control mice . (E,F). Incr ased gene expression of OSM a d OSMβR in high
fat–high fructose diet (HFHF) mice model. Quantitative real time PCR (q-PCR) a alysis of OSM (E) and
OSMβR (F) transcript levels in control mice (standard diet) and in mice fed with HFHF diet for 24 weeks.
Data are expressed as means ± SEM of three independent experiments (* p < 0.05 vs control mice).
OSM transcript levels were significantl i creased als in specimens obtained from NASH patients
as compared to those obtain fro patients showing simple steatosis (no NASH, Figure 2A); moreover,
OSM immunostaining was also significantly increased in sections from liver biopsies from NASH
patients and in cells characterized by macrophage-like morphology (i.e., CD68 positive) (Figure 2B).
3.2. OSM Effects on Profibrogenic Cells
On the basis of results suggesting the involvement of OSM in the early stage of experimental
NAFLD/NASH as well as in specimens from human NASH patients, we next analyzed the potential
direct pro-fibrogenic role of OSM on myofibroblast-like cells. Human immortalized LX2 cells and,
in parallel, human HSC/MFs in primary culture were exposed to human recombinant OSM (hrOSM) in
order to evaluate selected pro-fibrogenic phenotypic responses of this cells. Human LX2 cells as well as
HSC/MFs, that both positively responded to the potent mitogen and chemoattractant PDGF-BB (used
here as positive control), did not proliferate when exposed to hrOSM according to data obtained in both
the proliferation assay (Figure 3A and Figure S1A) and the BrdU incorporation assay (Figure S2A,B).
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However, hrOSM was able to stimulate chemotaxis and non-oriented migration in both LX2 cells
(Figure 3B,C) and HSC/MFs (Figure S1B,C).Cells 2020, 9, 28 9 of 26 
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Figure 2. (A,B). Increased expression of OSM in human patients with NASH or with simple steatosis
without NASH. (A) Quantitative real time PCR (q-PCR) analysis of OSM transcript levels in patients
with NASH or with simple steatosis without NASH. Data are expressed as means ± SEM of three
independent experiments (* p < 0.05 vs patients without NASH). (B) Immunohistochemistry analysis
for OSM and CD68 (a marker of human macrophages) on liver specimens obtained from human
patients with NASH. Original magnifications are indicated.
The response to hrOSM was based, as expected, on the expression of both LIFβR e OSMβR
receptor subunits in cultured cells; interestingly, treatment of LX2 and HSC/MFs cells with hrOSM
also determined a ignificant increa e of mRNA le ls for both receptors th t was d tect d 3 h after
OSM administration (Figure 4A,B and Figu e S3A,B). hrOSM, according to literature data on other cell
types, induced an increased, early and transient phosphorylation of STAT1, lasting from 15 min to 1 h
(Figure 4C and Figure S3C) as well as an increased and m r persistent (up t 6 h) phosphorylation of
STAT3 (Figure 4D and Figure S3D).
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also determined a significant increase of mRNA levels for both receptors that was detected 3 h after 
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Figure 3. ( – ) Effect of hu an reco binant S (hr S ) on proliferatio and igratio of LX2
cells. roliferation as ay (24 h, (A)), Boyden’s chamber assay (6 h, (B)) and wound healing assay (20 h,
(C)) were performed on LX2 cells exposed to PDGF-BB 10 ng/mL, used as positive control, or to hrOSM
10 ng/mL. Data in bar graphs represent mean ± SEM (n = 3, in triplicate) * p < 0.05, ** p < 0.01 versus
control value.
In both cell types OSM also induced an early (i.e., within 15–30 min) phosphorylation of ERK1/2
isoforms (Figure 5A and Figure S4A), JNK1/2 isoforms (Figure 5B and Figure S4B) and cAkt (Figure 5C
and Figure S4C). As expected, the phosphorylation of all proteins analyzed did not change in control
conditions at all experimental time points (Figure S5A,B).
In order to elucidate which signaling pathway had a key role in modulating cell migration, both cell
types were pre-treated with specific pharmacological inhibitors. Pre-treatment of cells with PD98059
(inhibitor of the ERK1/2 upstream kinase MEK-1) or SP600125 (inhibitor of the JNK1/2) or LY294002
(inhibitor of the Akt upstream kinase PI3K) significantly reduced either chemotaxis (Figure 6A,B and
Figure S6A,B) or chemokinesis (Figure 6C,D and Figure S6C,D) in both LX2 cells and HSC/MFs.
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In previous studies [12,13,26] we reported that exposure of human HSC/MFs to different
polypeptides (PDGF, MCP-1, VEGF) and to controlled conditions of moderate hypoxia resulted
in a significant increase of intracellular ROS levels. We then next performed experiments to investigate
whether intracellular generation of ROS may be critical also after exposure of LX2 and HSC/MFs to
hrOSM. In both cell types, OSM induced an early (within 1 h in LX2 cells and 15 min in HSC/MFs)
and significant increase in ROS-related intracellular fluorescence, a finding that was prevented
by pre-treating cells with the NADPH-oxidase pharmacological inhibitor apocynin (Figure 8 and
Figure S8A), that although not specific, has the advantage to inhibit all NAPDH oxidase isoforms
(NOX1, NOX2, and NOX4) expressed by hepatic MFs.Cells 2020, 9, 28 12 of 26 
 
 
Figure 5. (A–C) The cellular response to hrOSM involved different signal pathways. Western blotting 
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Apocynin also significantly inhibited OSM-induced chemotaxis in LX2 (Figure 9A,B) and in
HSC/MFs (Figure S8B,C), but was ineffective on OSM-dependent chemokinesis in both cell types
(Figure 9C,D and Figure S8D,E). Since OSM also involved activation of STAT1/STAT3 pathway, we
pre-treated both cell types with AG490, the pharmacological inhibitor of the STAT1/STAT3 upstream
kinase Jak-2; the use of AG490 resulted in a significant inhibition of non-oriented migration (Figure 9C,D
and Figure S8D,E) but did not apparently affect chemotaxis (Figure 9A,B and Figure S8B,C).
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In order to further elucidate the role of ROS in mediating the chemotactic response, we
performed more experiments by pre-treating LX2 with apocynin. Apocynin significantly inhibited
early phosphorylation of ERK1/2 isoforms, JNK1/2 isoforms and c-Akt (Figure 10A,C,E), confirming the
critical role of intracellular ROS in mediating OSM-dependent chemotaxis of LX2, already described
for other chemotactic peptides like PDGF-BB, CCL2 (MCP-1) and VEGF in HSC/MFs [13]. As expected,
apocynin alone, did not affect the state of phosphorylation of ERK1/2, JNK1/2 as well as of c-Akt
(Figure 10B,D,F).Cells 2020, 9, 28 13 of 26 
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Figure 6. (A,B) Involvement of signal transduction pathways in the modulation of OSM-dependent 
migration of LX2 cells. Boyden’s chamber assay (A) was performed on LX2 cells exposed to hrOSM 
10 ng/mL for 6 h. In some experimental conditions LX2 cells were pre-treated for 30 min with specific 
pharmacological inhibitors PD98059 (MEK-1 inhibitor), SP600125 (JNK 1/2 inhabitor), LY294002 (Akt 
inhibitor) and then exposed or not to hrOSM 10 ng/mL for 6 h. Data in bar graphs represent mean ± 
SEM (n = 3, in triplicate). *p < 0.05 versus control value; #p < 0.05, versus OSM value. (B) Representative 
images of cells on filter from Boyden’s chamber assay stained with crystal violet. Original 
magnification is indicated. (C,D) Involvement of signal transduction pathways in the modulation of 
OSM-dependent migration of LX2 cells. Wound healing assay (C) was performed on LX2 cells 
exposed to hrOSM 10 ng/mL for 20 h. In some experimental conditions LX2 cells were pre-treated for 
30 min with specific pharmacological inhibitors PD98059 (MEK-1 inhibitor), SP600125 (JNK 1/2 
inhibitor), LY294002 (Akt inhibitor) and then exposed or not to hrOSM 10 ng/mL for 20 h. Data in bar 
graphs represent mean ± SEM (n = 3, in triplicate). *p < 0.05 versus control value #p < 0.05, versus OSM 
value. (D) Representative images of cells invading the artificial wound stained with crystal violet. 
Original magnification is indicated. 
Since literature data reported a role of OSM in triggering epithelial mesenchymal transition 
(EMT), we next performed experiments to evaluate a possible role of OSM in inducing EMT markers. 
However, in both cell types OSM was not able to affect typical EMT markers, like fibronectin and E-
cadherin (Figures 7 and S7). 
Figure 6. (A,B) Involvement of signal transduction pathways in the modulation of OSM-dependent
migration of LX2 cells. Boyden’s chamber assay (A) was performed on LX2 cells exposed to hrOSM
10 ng/mL for 6 h. In some experimental conditions LX2 cells were pre-treated for 30 min with specific
pharmacological inhibitors PD98059 (MEK-1 inhibitor), SP600125 (JNK 1/2 inhabitor), LY294002 (Akt
inhibitor) and then exposed or not to hrOSM 10 ng/mL for 6 h. Data in bar graphs represent mean± SEM
(n = 3, in triplicate). * p < 0.05 versus control value; # p < 0.05, versus OSM value. (B) Representative
images of cells on filter from Boyden’s chamber assay stained with crystal violet. Original magnification
is indicated. (C,D) Involvement of signal transduction pathways in the modulation of OSM-dependent
migration of LX2 cells. Wound healing assay (C) was performed on LX2 cells exposed to hrOSM
10 ng/mL for 20 h. In some experimental conditions LX2 cells were pre-treated for 30 min with
specific pharmacological inhibitors PD98059 (MEK-1 inhibitor), SP600125 (JNK 1/2 inhibitor), LY294002
(Akt i hibitor) and then exposed or not to hrOSM 10 ng/mL for 20 h. Data in bar graphs represent
mean ± SEM (n = 3, in triplicate). * p < 0.05 versus c ntr l value # p < 0.05, versus OSM value.
(D) Repr sentative images of cells invading the artificial wound tained with crystal violet. Original
magnification is indic ted.
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Since in a previous study [13] we showed a peculiar biphasic nature of HSC/MFs migration in
response to different polypeptides and controlled hypoxic conditions, we performed experiments to
investigate whether the late non-oriented migration stimulated by OSM may depend on VEGF-A release.
Moreover, since other researchers [19,20] proposed a role for OSM in orchestrating hypoxia-modulated
hepatic processes involving the hypoxia inducible factor 1 (HIF-1), we performed experiments to
evaluate whether OSM may contribute to HIF-1α recruitment/stabilization. In LX2 cells hrOSM
induced an increase of HIF1α transcription (Figure 11A) which may depend on intracellular ROS
production and JAK/STAT signaling, as suggested by inhibition observed in the presence of apocynin
or AG490 (Figure 11B). Furthermore, the exposure of LX2 to rhOSM also induced an increase in HIF1α
recruitment/stabilization; this event was significant after 3 h and remained significantly up-regulated
until 24 h, although a decreasing trend was observed after 6 h (Figure 11C).Cells 2020, 9, 28 15 of 26 
 
 
Figure 7. The effect of hrOSM in EMT process. Western blotting analysis of Fibronectin and E-
cadherin in LX2 cells exposed or not (indicated as C) to hrOSM 10 ng/mL (starting from 15 min up to 
24 h). Equal loading was confirmed by reprobing the same membrane with the β-action. 
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that although not specific, has the advantage to inhibit all NAPDH oxidase isoforms (NOX1, NOX2, 
and NOX4) expressed by hepatic MFs.
 
Figure 8. hrOSM dependent induction of migration relies on intracellular generation of ROS. Flow 
citometry analysis to evaluate ROS intracellular generation in LX2 cells untreated or treated for 1 h 
with hrOSM 10 ng/mL or with H2O2 100 μM for 15 min, used as positive control, or pre-treated for 1 
h with the pharmacological inhibitor of NADPH oxidase (APO: apocynin 250 μM) and then exposed 
to hrOSM 10 ng/mL for 1 h. *p < 0.05, **p < 0.01 versus control value, #p < 0.05 versus OSM value. 
Apocynin also significantly inhibited OSM-induced chemotaxis in LX2 (Figure 9A,B) and in 
HSC/MFs (Figure S8B,C), but was ineffective on OSM-dependent chemokinesis in both cell types (Figures 
9C,D and S8D,E). Since OSM also involved activation of STAT1/STAT3 pathway, we pre-treated both cell 
types with AG490, the pharmacological inhibitor of the STAT1/STAT3 upstream kinase Jak-2; the use of 
AG490 resulted in a significant inhibition of non-oriented migration (Figures 9C,D and S8D,E) but did not 
apparently affect chemotaxis (Figures 9A,B and S8B,C). 
Figure 7. The effect of hrOSM in EMT process. Western blotting analysis of Fibronectin and E-cadherin
in LX2 cells exposed or not (indicated as C) to hrOSM 10 ng/mL (starting from 15 min up to 24 h). Equal
loading was confirmed by reprobing the same membrane with the β-action.
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Apocynin also significantly inhibited OSM-induced chemotaxis in LX2 (Figure 9A,B) and in 
HSC/MFs (Figure S8B,C), but was ineffective on OSM-dependent chemokinesis in both cell types (Figures 
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Figure 8. hr S dependent induction of migration relies on intracellular generation of ROS. Flow
citometry analysis to evaluate ROS intracellular generation in LX2 cells untreated or treated for 1 h
with hrOSM 10 ng/mL or with H2O2 100 µM for 15 min, used as positive control, or pre-treated for 1 h
with the pharmacological inhibitor of NADPH oxidase (APO: apocynin 250 µM) and then exposed to
hrOSM 10 ng/mL for 1 h. * p < 0.05, ** p < 0.01 versus control value, # p < 0.05 versus OSM value.
Cells 2020, 9, 28 15 of 24
VEGF-A is a classic target gene of HIF1 (and then of HIF1α) and we previously demonstrated that
this growth factor was able to stimulate migration of HSC/MFs [13]. Accordingly, we next investigated
the involvement of VEGF-A in OSM dependent non-oriented migration of LX2 cells and HSC/MFs.
Results indicate that exposure of LX2 cells to hrOSM increased both transcript (Figure 12A) and protein
levels of VEGF-A (Figure 12C) and that these events occurred 24 h after hrOSM treatment, the time
point at which VEGF-A is also released in the medium (Figure 12B). Homologous results were obtained
also in HSC/MFs (Figure S9A–C).
In order to further investigate the relevance of OSM-dependent induction of VEGF-A expression,
conditioned media obtained by cells exposed to hrOSM were collected after different time points
(starting from 16 h to 48 h) and then used in the wound healing assay. OSM conditioned medium
induced a significant stimulation of non-oriented migration at 48 h in both LX2 and HSC/MFs
(Figure 12D and Figure S9D). Non-oriented migration was significantly inhibited by pre-treating cells
with either a pharmacological inhibitor of VEGF receptor type 2 (VEGF-R2) tyrosine kinase (SU1498)
or with a neutralizing antibody directed against VEGF-R2. As expected, apocynin alone did not affect
basal non oriented migration (Figure 12D and Figure S9D). These data then suggest a pro-migratory
role for VEGF-A released in the OSM conditioned medium (Figure 12D and Figure S9D).
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Figure 9. (A,B) OSM-dependent chemotaxis relies on ROS intracellular generation. Boyden’s chamber 
assay (A) was performed on LX2 cells treated with hrOSM 10 ng/mL for 6 h or, where indicated, pre-
treated for 1 h with the pharmacological inhibitor of the NADPH oxidase (APO: apocynin 250 μM) or 
with the JAK2 inhibitor (AG490 100 μM) and then exposed or not to hrOSM 10 ng/mL for 6 h. *p < 
0.05, versus control value, #p < 0.05 versus OSM value. (B) Representative images of cells on filter 
from Boyden’s chamber assay stained with crystal violet. Original magnification is indicated. (C,D) 
OSM-dependent non-oriented migration relies on STATI 1/3 activation. Wound healing assay (C) was 
performed on LX2 cells treated with hrOSM 10 ng/mL for 20 h or, where indicated, pre-treated for 1 h with 
the the pharmacological inhibitor of the NADPH oxidase (APO: apocynin 250 μM) or with the JAK2 
inhibitor (AG490 100 μM) and then exposed or not to hrOSM 10 ng/mL for 20 h. *p < 0.05, versus control 
value, #p < 0.05 versus OSM value. (D) Representative images of cells invading the artificial wound stained 
with crystal violet. Original magnification is indicated. 
In order to further elucidate the role of ROS in mediating the chemotactic response, we 
performed more experiments by pre-treating LX2 with apocynin. Apocynin significantly inhibited 
early phosphorylation of ERK1/2 isoforms, JNK1/2 isoforms and c-Akt (Figure 10A,C,E), confirming 
the critical role of intracellular ROS in mediating OSM-dependent chemotaxis of LX2, already 
described for other chemotactic peptides like PDGF-BB, CCL2 (MCP-1) and VEGF in HSC/MFs [13]. 
As expected, apocynin alone, did not affect the state of phosphorylation of ERK1/2, JNK1/2 as well as 
of c-Akt (Figure 10 B,D,F). 
Figure 9. ( , ) S -dependent che otaxis relies on ROS intracel ular generation. Boyden’s chamber
as ay ( ) LX2 cells treated wit hrOSM 10 ng/mL for 6 h or, where indicated,
pre-tr ated for 1 h wit the pharmacological inhibit r of the NADPH oxidase (APO: apocy in 250 µM)
or with the JAK2 inhibitor (AG49 100 µM) and th n exposed or n t to hrOSM 10 ng/mL for 6 h.
* p < 0.05, versus c ntro value, # p < 0.05 versus OSM value. (B) Representative images of cells on
filter from Boyden’s chamber a s y stained with crystal violet. Original magnificatio is indicated.
(C,D) OSM- pendent no -oriented mig ation relies on STATI 1/3 activatio . Wound healing assay
(C) was performed on LX2 c lls treated with hrOSM 10 ng/mL for 20 h or, wh re indicated, pre-treated
for 1 wit the the pharmacological in ibitor of the NADPH oxidase (APO: apocynin 250 µM) or with
the JAK2 inhibitor (AG490 100 µM) and then exposed or not to hrOSM 10 ng/mL for 20 h. * p < 0.05,
vers s control alue, # p < 0.05 versus OSM value. (D) Representative images of cells invading the
artificial wound stained with crystal violet. Original magnification is indicated.
Finally, further preliminary experiments were performed in order to verify whether hrOSM,
which is known to be mainly released by macrophages and lymphocytes, may also modulate the
pro-inflammatory phenotypic response of LX2. The treatment of LX2 cells with hrOSM resulted in an
increased transcription of CCL2, IL6, and TNFα (Figure 13A–C).
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1/2 (C,D) and c-Akt (E,F) in LX2 cells exposed to hrOSM 10 ng/mL for 15 and 30 min or, where 
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250 μM) and then exposed to hrOSM 10 ng/mL. In some experiments LX2 cells were treated with the 
inhibitor apocynin alone for 1 h (B,D,F) and incubated for additional 30 min. Equal loading was 
confirmed by re-probing the same membrane with un-phosphorylated protein. 
Since in a previous study [13] we showed a peculiar biphasic nature of HSC/MFs migration in 
response to different polypeptides and controlled hypoxic conditions, we performed experiments to 
investigate whether the late non-oriented migration stimulated by OSM may depend on VEGF-A release. 
Moreover, since other researchers [19,20] proposed a role for OSM in orchestrating hypoxia-modulated 
hepatic processes involving the hypoxia inducible factor 1 (HIF-1), we performed experiments to evaluate 
whether OSM may contribute to HIF-1α recruitment/stabilization. In LX2 cells hrOSM induced an 
increase of HIF1α transcription (Figure 11A) which may depend on intracellular ROS production and 
JAK/STAT signaling, as suggested by inhibition observed in the presence of apocynin or AG490 (Figure 
11B). Furthermore, the exposure of LX2 to rhOSM also induced an increase in HIF1α 
recruitment/stabilization; this event was significant after 3 h and remained significantly up-regulated until 
24 h, although a decreasing trend was observed after 6 h (Figure 11C). 
Figure 10. (A–F) Involvement of S -dependent intracellular ROS generation in the activation of
specific signal pathways. Western blotting analysis of phosphorylated levels of ERK 1/2 (A,B), JNK 1/2
(C,D) and c-Akt (E,F) in LX2 cells exposed to hrOSM 10 ng/mL for 15 and 30 min or, where indicated,
pre-treated 1 h with the pharmacological inhibitor of the NADPH oxidase (APO: apocynin 250 µM)
and then exposed to hrOSM 10 ng/mL. In some experiments LX2 cells were treated with the inhibitor
apocynin alone for 1 h (B,D,F) and incubated for additional 30 min. Equal loading was confirmed by
re-probing the same membrane with un-phosphorylated protein.
Moreover, the pre-treatment of cells with apocynin or with AG490 reduced CCL2 transcription
(Figure 14). The treatment with apocynin and AG490 did not affect the mRNA transcript levels of CCl2.
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Figure 11. (A–C) Involvement of intracellular generation of ROS in the OSM-dependent recruitment/ 
stabilization of HIF1α. Quantitative real time PCR (q-PCR) analysis of HIF1α transcript levels in LX2 
exposed to hrOSM 10 ng/mL up to 24 h (A) or in cells pre-treated with the pharmacological inhibitor 
of the NADPH oxidase (APO: apocynin 250 μM) or with the JAK2 inhibitor (AG490 100 μM) for 1 h 
and then exposed or not to OSM 10 ng/mL for 6 h (times in which HIF1α transcript levels were more 
significant). (B) Data are expressed as means ± SEM of three independent experiments. *p < 0.05, **p 
< 0.01 versus control value, #p < 0.05; versus OSM value. (C) Western blotting analysis of HIF1α 
protein levels in LX2 untreated or treated with hrOSM 10 ng/mL (from 15 min to 24 h). Equal loading 
was confirmed by re-probing the same membrane with β-action. 
VEGF-A is a classic target gene of HIF1 (and then of HIF1α) and we previously demonstrated 
that this growth factor was able to stimulate migration of HSC/MFs [13]. Accordingly, we next 
investigated the involvement of VEGF-A in OSM dependent non-oriented migration of LX2 cells and 
HSC/MFs. Results indicate that exposure of LX2 cells to hrOSM increased both transcript (Figure 
12A) and protein levels of VEGF-A (Figure 12C) and that these events occurred 24 h after hrOSM 
treatment, the time point at which VEGF-A is also released in the medium (Figure 12B). Homologous 
results were obtained also in HSC/MFs (Figure S9A–C). 
In order to further investigate the relevance of OSM-dependent induction of VEGF-A expression, 
conditioned media obtained by cells exposed to hrOSM were collected after different time points (starting 
from 16 h to 48 h) and then used in the wound healing assay. OSM conditioned medium induced a 
significant stimulation of non-oriented migration at 48 h in both LX2 and HSC/MFs (Figures 12D and 
S9D). Non-oriented migration was significantly inhibited by pre-treating cells with either a 
Figure 11. (A–C) Involvement of intracellular generation of ROS in the OSM-dependent recruitment/
stabilization of HIF1α. Quantitative real time PCR (q-PCR) analysis of HIF1α transcript levels in LX2
exposed to hrOSM 10 ng/mL up to 24 h (A) or in cells pre-treated with the pharmacological inhibitor
of the NADPH oxidase (APO: apocynin 250 µM) or with the JAK2 inhibitor (AG490 100 µM) for 1 h
and then exposed or not to OSM 10 ng/mL for 6 h (times in which HIF1α transcript levels were more
significant). (B) Data are expressed as means ± SEM of three independent experiments. * p < 0.05,
** p < 0.01 versus control value, # p < 0.05; versus OSM value. (C) Western blotting analysis of HIF1α
protein levels i LX2 untr ated or treated with hrOS 10 ng/mL (from 15 min to 24 h). Equal loading
was confirmed by re-probing the same membrane with β-action.
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Figure 12. (A–D) Involvement of VEGF-A in OSM-dependent non oriented migration. (A) 
Quantitative real time PCR (q-PCR) analysis of VEGF-A transcript levels in LX2 exposed to hrOSM 
10 ng/mL up to 24 h. Data are expressed as means ± SEM of three independent experiments. *p < 0.05, 
**p < 0.01 versus control value. (B) Immunoprecipitation analysis of VEGF-A released in the medium 
of LX2 cells treated with hrOSM 10 ng/mL up to 48 h. (C)Western Blotting analysis of VEGF protein 
levels in LX2 cells treated with hrOSM 10 ng/mL up to 48 h. Equal loading was confirmed by re-
probing the same membrane with p-actin. (D) Wound healing assay was performed in LX2 untreated 
or exposed to conditioned medium collected after 48 h of treatment with OSM (OSMm) for 20 h. In 
some experiments LX2 cells were pre-treated with the neutralizing antibody for VEGFR2 or with the 
pharmacological inhibitor of VEGFR2, SU1498, for l h and then exposed or not to OSMm for 20 h. **p 
< 0.01 versus control value, #p < 0.05; versus OSMm value. Representative images of cells invading 
the artificial wound stained with crystal violet. Original magnification is indicated. 
Finally, further preliminary experiments were performed in order to verify whether hrOSM, 
which is known to be mainly released by macrophages and lymphocytes, may also modulate the pro-
inflammatory phenotypic response of LX2. The treatment of LX2 cells with hrOSM resulted in an 
increased transcription of CCL2, IL6, and TNFα (Figure 13A–C). 
Figure 12. (A–D) Involvement of VEGF-A in OSM-dependent non oriented migration. (A) Quantitative
real time PCR (q-PCR) analysis of VEGF-A transcript levels in LX2 exposed to hrOSM 10 ng/mL up to
24 h. Data are expressed as means ± SEM of three independent experiments. * p < 0.05, ** p < 0.01
versus control value. (B) Immunoprecipitation analysis of VEGF-A released in the medium of LX2
cells treated with hrOSM 10 ng/mL up to 48 h. (C)Western Blotting analysis of VEGF protein levels in
LX2 cells treated with hrOSM 10 ng/mL up to 48 h. Equal loading was confirmed by re-probing the
same membrane with p-actin. (D) Wound healing assay was performed in LX2 untreated or exposed to
conditioned medium collected after 48 h of treatment with OSM (OSMm) for 20 h. In some experiments
LX2 cells were pre-treated with the neutralizing antibody for VEGFR2 or with the pharmacological
inhibitor of VEGFR2, SU1498, for l h and then exposed or not to OSMm for 20 h. ** p < 0.01 versus
control value, # p < 0.05; versus OSMm value. Representative images of cells invading the artificial
wound stained with crystal violet. Original magnification is indicated.
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Figure 13. (A–C) OSM modulation of LX2 pro-inflammatory response. Quantitative real time PCR (q-
PCR) analysis of CCL2 (A), TNF-α (B) and IL-6 (C) transcript levels in LX2 exposed to hrOSM 10 
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4. Discussion
Migration of hepatic MFs is a typical and distinctive pro-fibrogenic feature that allows these cells
to align with inflammatory cells along fibrotic septa during liver fibrosis progression. This event
occurs during CLDs in response to different stimuli and mediators, including polypeptide mediators,
ROS as well as hypoxia [6,7,11]. In this scenario, literature data have already proposed a role for
OSM in modulating CLD progression, likely by modulating defined processes like development,
regeneration, hematopoiesis, and angiogenesis [20,22]. OSM is normally expressed in Kupffer cells
and its expression, variable in normal livers, increases in cirrhotic livers [21]; it was proposed that this
cytokine may up-regulate selected pro-fibrogenic responses of HSCs, including synthesis of collagen
I and TIMP1 [22]. Along these lines, the present study was designed to investigate whether OSM
may be involved also in NAFLD progression and may directly modulate other relevant pro-fibrogenic
responses of MFs like proliferation and migration. Data in this study provide evidence that OSM is
potentially involved in NAFLD progression as shown by data obtained by analyzing either the livers
of mice fed on different dietary protocols (i.e., mice fed on either MCD, CDAA or HFHF diets) or in
human liver specimens from NAFLD/NASH patients. In particular, human data indicate that OSM
is up-regulated in NASH patients but not in patients that have only histological evidence of simple
steatosis. Similarly, OSM expression increases in murine livers in parallel with the development of
NASH-associated fibrosis. In our knowledge, this is the first report involving up-regulation of OSM
expression in experimental and clinical progressive NAFLD, and further experiments and analyses are
currently in progress in order to verify whether this mediator (or its related receptor subunits) may
be validated as a marker of NAFLD progression and/or may have prognostic significance. This is a
potentially relevant issue for a disease that is rapidly emerging as the most relevant CLD worldwide
and that affects a large number of individuals in the general population.
Concerning the putative pro-fibrogenic role of OSM, already proposed by two earlier studies [18,22]
and by a more mechanistic and recent one [24], we here propose that OSM is indeed able to directly
target hepatic MFs. In particular, the present study shows that OSM can induce migration of both
LX2 and HSC/MFs and that OSM dependent migration occurs as a biphasic process involving distinct
but interrelated early and late events. These data are fully in agreement with previously published
results investigating the pro-migratory action of chemotactic polypeptides and controlled conditions
of hypoxia [12,13]. This conclusion is supported by several lines of evidence. First, OSM-induced
early migration is triggered by ROS released within few minutes, likely as a consequence of the
parallel activation of the ROS-generating membrane complex NADPH-oxidase, similarly to what
described for HSC/MFs in response to other chemoattractant polypeptides [13]. The intracellular
generation of ROS after OSM treatment was demonstrated by performing the DCFH-DA technique
in presence or absence of the NADPH pharmacological inhibitor apocynin. This inhibitor, although
not specific/selective, has the advantage to block all NADPH-oxidase (NOX) isoforms expressed by
hepatic MFs (i.e., NOX1, NOX2, and NOX4). Apocynin pretreatment reduced early LX2 and HSC/MFs
chemotaxis, whereas it was ineffective on late OSM-dependent migration. Our data also suggest,
as previously demonstrated for other stimuli [13,25], that the rise of intracellular ROS generation is
related to an early redox-dependent phosphorylation (i.e., activation) of ERK1/2 and JNK1/2 isoforms
with a kinetic compatible with that of ROS release. This notion is supported by data demonstrating a
reduction of chemotaxis in both cell types obtained by pre-treating cells with specific pharmacological
inhibitors of ERK1/2 and JNK1/2 (PD98059 and SP600125, respectively). A direct link between the
increase on intracellular levels of ROS and redox-related activation of both ERK1/2 and JNK1/2 it is
now well established in the redox signaling scenario. It has been suggested that the increased kinase
activity is likely to be the result of direct activation of defined signaling components or of inhibition of
phosphatases responsible for the negative feed-back control of activated signaling pathways (like JNK
specific phosphatases or, more generally, protein tyrosine phosphatases) [26–28]. The involvement of
these different signaling pathways is in line with that observed for all the cytokine belonging to IL-6
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type family, even if the signal transduction pathways of these cytokines, still currently investigated,
are sometimes suggested to be cell-type specific.
A second role for OSM-related increase in intracellular ROS levels is related to the modulation of
JAK/STAT signaling pathway. This event has been already described by Madamanchi et al. in vascular
smooth muscle cells in which JAK2 was rapidly activated after treatment with hydrogen peroxide and
both STAT1 and STAT3 were phosphorylated on tyrosine residues to then translocate to the nucleus in a
JAK2-dependent manner [29]. Moreover, Authors showed that the inhibition of JAK2 activity by means
of AG-490 partially inhibited hydrogen peroxide-induced ERK2 activity, suggesting that JAK protein is
upstream of the Ras/ERK pathway and have a key role in the adaptive response to oxidative stress [29].
Along these lines, also in LX2 and HSC/MFs the early intracellular generation of ROS is able to sustain
late migration by the involvement of JAK/STAT3 signaling pathway; this notion is supported by results
showing AG490-dependent inhibition of JAK pathway and apocynin-dependent inhibition of STAT3
pathway. These results suggest that OSM can affect cell migration and are in agreement with a study in
which the inhibition of JAK family members, in particular of JAK1, significantly reduced activation,
proliferation, and migration of rat hepatic stellate cells [29]. Our results are also in agreement with
literature data showing a role for JAK/STAT pathway in the modulation of liver fibrosis, as in the case
of STAT3 activation in hepatic stellate cells treated with IL-6 and leptin [30,31].
Results obtained in the wound healing assay also provided evidence that OSM-dependent non
oriented migration required late HIF1-dependent expression and release of VEGF-A. These results are
homologous to those reported for exposure to hypoxic conditions and are potentially in agreement
with literature data showing a role for OSM in modulating hypoxia-regulated processes (including
hematopoiesis, angiogenesis, liver development, and regeneration), then suggesting a possible cross-talk
between OSM and hypoxia signaling pathways [23]. According to literature data obtained in different
cell types [19], we report that in both LX2 cells and HSC/MFs OSM can induce a significant up-regulation
of HIF1α protein levels under normoxic conditions. Interestingly, as previously reported for HSC/MFs
exposed to hypoxia [26], HIF1α up-regulation was associated with increased production and release of
VEGF-A that, in turn, was the real responsible for late OSM-dependent migration. This notion was
supported by the following observations: (i) OSM-related increase in HIF1α stabilization was rapidly
detected (starting from 3 h and persisting for the entire experimental protocol; (ii) VEGF-A was released
in the extracellular medium of cells exposed to OSM only after 24 h in LX2 cells; (iii) conditioned
medium obtained from cells treated with OSM efficiently stimulated only late non-oriented migration;
and (iv) both pre-treatment of cells with SU1498, a pharmacological inhibitor of the tyrosine-kinase
receptor subunit of VEGFR-2 and with a neutralizing antibody for VEGFR-2 inhibited non-oriented
OSM-dependent migration. These results obtained in both LX2 cells and HSC/MFs are in agreement with
data obtained in previous studies related to the pro-migratory action of VEGF-A [26,32], and suggest a
potential role for OSM-dependent expression and release of VEGF-A.
Finally, although in our experimental conditions OSM was found ineffective on the synthesis of
collagen I and of TIMP1 (data not shown), differently from what reported by others [33], we additionally
observed that hrOSM up-regulated in LX2 cells transcript levels of the chemokine CCL2, the most
relevant chemokine during both experimental and human conditions of progressive NAFLD [34],
as well as of the pro-inflammatory cytokines TNF e IL-6. However, these data are preliminary and
further experiments will be necessary to mechanistically characterize this issue.
In conclusion, data reported in the present study provide novel evidence adding further knowledge
on the proposed pro-fibrogenic role of OSM in the progression of CLD and suggest for the first time a
possible involvement of this cytokine in the progression of NAFLD.
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